Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 8/20 | 0.43 |
| ▸ | F10 | P00742 | 7/20 | 0.43 |
| ▸ | F11 | P03951 | 7/20 | 0.43 |
| ▸ | PGR | P06401 | 4/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 1/20 | 0.33 |
| ▸ | PRKACG | P22612 | 1/20 | 0.33 |
| ▸ | PRKACB | P22694 | 1/20 | 0.33 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141149 | 0.86 | F10 (0.42) | F7F10F11PGRCYP11B2 | |
| SCHEMBL2729946 | 0.84 | F7 (0.50) | F7F10F11PGR | |
| SCHEMBL2137574 | 0.83 | F7 (0.38) | F7F10F11 | |
| SCHEMBL2135732 | 0.82 | ALDH1A1 (0.41) | F7F10F11PGR | |
| SCHEMBL2136174 | 0.82 | F7 (0.38) | F7F10F11PGRKDM1A | |
| SCHEMBL2134882 | 0.81 | F11 (0.41) | F7F10F11PGRKDM1A | |
| SCHEMBL2135630 | 0.80 | F7 (0.37) | F7F10F11PGRCYP11B2 | |
| SCHEMBL11024205 | 0.79 | F11 (0.52) | F7F10F11PGR | |
| SCHEMBL2139861 | 0.79 | MAPK1 (0.40) | F7F10F11PGRKDM1A | |
| SCHEMBL2141230 | 0.78 | F11 (0.39) | F7F10F11PGRKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | claimed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | claimed |
| EP-2630124-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-08-28 | — | — | EP | claimed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | claimed |
| EP-2630124-B1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8546427-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2630124-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-08-28 | — | — | EP | disclosed |
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052372-A1 | TETRAHYDROQUINOLINE DERIVATIVES USED AS AMPK ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101127-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | PRKAG1, PRKAB1, PRKAG2 | F7 4761/4885F10 4686/4885F11 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.